UK cancer research bodies agree commercial "skills swap"
This article was originally published in Clinica
Executive Summary
The commercial arms of charity Cancer Research UK (CRUK) and of the UK government's Medical Research Council (MRC) yesterday signed an agreement to swap R&D rights. The initiative promises to "accelerate the translation of early scientific research into patient benefit", in diagnostics as well as therapeutics, Clinica has learnt.
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.